Heart Matters

Episoder

• 
  Overcoming Challenges in ATTR-CM Diagnosis 20.08.2026 3min

  Guest: Sumeet Mitter MD, MSc, FACC Even with advances in noninvasive imaging, diagnosing ATTR-CM isn’t always straightforward. That's why Dr. Sumeet Mitter joins us to discuss how we can address key challenges in diagnosis and navigate the path to treatment. He's the Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia.
• 
  Multidisciplinary Care in ATTR-CM: Building the Right Team 20.08.2026 3min

  Guest: Sumeet Mitter MD, MSc, FACC Because transthyretin amyloid cardiomyopathy (ATTR-CM) is a systemic disease, effective ATTR-CM management requires expertise beyond cardiology. Dr. Sumeet Mitter joins us to discuss the roles of neurology, hematology-oncology, genetic counseling, and nephrology in caring for these patients. He's the Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia.
• 
  Building Clinical Expertise in ATTR-CM Management 20.08.2026 2min

  Guest: Sumeet Mitter MD, MSc, FACC As advances in RNA silencers, gene-editing technologies, and immunotherapy reshape the ATTR-CM landscape, it's important to stay informed and build confidence navigating this increasingly complex field. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia, shares practical advice about navigating the nuances of this rare disease.
• 
  The Future of ATTR-CM Care: A Look at What's Next 20.08.2026 4min

  Guest: Sumeet Mitter MD, MSc, FACC The future of ATTR-CM care may extend beyond slowing disease progression to detecting it sooner—and potentially reversing its effects. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia, explores emerging innovations that could open the door to earlier intervention, combination therapy, and even one-time treatment strategies.
• 
  Managing Acute PE: Updates from the 2026 AHA/ACC Guideline 20.08.2026 10min

  Host: Mary Leuchars, MD Guest: Mark Creager, MD The 2026 American College of Cardiology/American Heart Association Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults introduces a new clinical categorization framework to help evaluate risk and determine the appropriate care setting and treatment for patients with acute pulmonary embolism. Review key updates as Dr. Mary Leuchars sits down with Dr. Mark Creager, chair of the guideline writing committee. He's also a Professor of Medicine and Professor of Surgery at the Geisel School of Medicine at Dartmouth.
• 
  From Goals to Action: Multisociety Guidance on Lipid Management 19.08.2026 4min

  Guest: Ann Marie Navar, MD, PhD With LDL cholesterol goals reinstated in the 2026 American College of Cardiology and American Heart Association Guideline on the Management of Dyslipidemia, we now have a clearer framework for intensifying lipid-lowering therapy. Dr. Ann Marie Navar explains how to select nonstatin therapies based on the degree of LDL lowering needed, patient preferences, and the treatment most likely to help patients achieve their LDL goals. Dr. Navar is an Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, and she served on the Guideline Writing Committee.
• 
  Managing Dyslipidemia: 2026 ACC/AHA Guideline Updates 19.08.2026 4min

  Guest: Roger Blumenthal, MD What do the 2026 American College of Cardiology (ACC) and American Heart Association (AHA) dyslipidemia guideline updates mean for patient care? Join Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, as he reviews key recommendations that can help us personalize cardiovascular risk reduction and improve long-term prevention. Dr. Blumenthal is the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.
• 
  How PCSK9 Inhibition Lowers LDL Cholesterol 19.08.2026 2min

  Guest: Ann Marie Navar, MD, PhD How does PCSK9 inhibition lower LDL cholesterol? Find out as Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, explains the biology behind this therapeutic approach.
• 
  Enlicitide for LDL-C Management: Insights from CORALreef Lipids 19.08.2026 4min

  Guest: Ann Marie Navar, MD, PhD The CORALreef Lipids trial helped establish the clinical evidence supporting the FDA approval of enlicitide for LDL-C management. Join Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, for a discussion of the trial's efficacy, safety, and durability. She also explores key considerations for integrating this therapy into clinical practice.
• 
  Risk Prediction with the PREVENT-ASCVD Equations 19.08.2026 2min

  Guest: Roger Blumenthal, MD As the drivers of cardiovascular disease have shifted over time, so have the tools used to estimate risk. Dr. Roger Blumenthal explains why the PREVENT-ASCVD equations represent an important advance over traditional models and what that means for more accurate, individualized preventive care. Dr. Blumenthal is the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.
• 
  The Patient You Might Be Missing: Severe Hypertriglyceridemia in Clinical Practice 14.08.2026 16min

  Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erin D. Michos, MD, MHS Severe hypertriglyceridemia (sHTG) affects more than 3 million people, but it often flies under the clinical radar.1-3 When triglycerides are at or above a 500 mg/dL threshold, it’s no longer just an isolated lab value—it’s a level of hypertriglyceridemia where the clinical implications change, and where a more careful evaluation for underlying causes and risk becomes important.4 That’s why Dr. Charles Turck sits down with Dr. Erin Michos to discuss what sHTG is, why it’s so important to identify, and how we can effectively manage this condition to improve patients’ overall health and reduce complication risk. Dr. Erin Michos is a Professor of Medicine, Director of Women’s Cardiovascular Health, and Associate Director of Preventive Cardiology at Johns Hopkins University School of Medicine. References: Saadatagah S, Larouche M, Naderian M, et al. Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology. Am J Prev Cardiol. 2025;22:100978. doi:10.1016/j.ajpc.2025.100978 Sanchez RJ, Ge W, Wei W, Ponda MP, Rosenson RS. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 2021;20(1):72. doi:10.1186/s12944-021-01488-8 Sikora Kessler A, Baum SJ, Kutrieb E, et al. Rates …
• 
  Evaluating ASCVD Risk with the CPR Framework 10.08.2026 4min

  Guest: Roger Blumenthal, MD The 2026 American College of Cardiology (ACC) and American Heart Association (AHA) Guideline on the Management of Dyslipidemia highlights the CPR framework—Calculate, Personalize, Reclassify, and Reassess—to support individualized atherosclerotic cardiovascular disease (ASCVD) risk assessment and treatment decisions. Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, joins us to explain how clinicians can combine PREVENT risk estimates with risk-enhancing factors, coronary artery calcium scoring, and shared decision-making to improve cardiovascular prevention strategies. Dr. Blumenthal is also the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.
• 
  Looking Ahead in ATTR-CM Care: Improving Diagnosis, Outcomes, and Equity 02.07.2026 3min

  Guest: Frederick Ruberg, MD What will the future of transthyretin amyloid cardiomyopathy (ATTR-CM) care look like? Dr. Frederick Ruberg joins us to share his perspective on the advances that may shape the next phase of patient care, from screening and therapeutic strategies to expanded genetic testing aimed at identifying patients earlier. He's the Chief of Cardiovascular Medicine at Boston Medical Center and Thomas J. Ryan Professor of Cardiovascular Medicine at Boston University Chobanian and Avedisian School of Medicine.
• 
  Hypertension in Women: Cardiovascular Risk Across the Lifespan 01.07.2026 18min

  Host: Shelina Ramnarine, PhD Guest: Payal Kohli, MD, FACC In women, hypertension follows a distinct biological and clinical course that evolves across reproductive and menopausal transitions, but its long-term implications remain underrecognized and undertreated. In this expert-led discussion, Dr. Shelina Ramnarine and Dr. Payal Kohli examine key considerations in managing hypertension in women and explore practical strategies to improve risk assessment and patient education. Dr. Kohli is an Associate Adjunct Professor at Johns Hopkins University and Duke University, as well as the Founder and Medical Director of Cherry Creek Heart in Aurora, Colorado. This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.
• 
  Early Recognition of ATTR-CM: Key Signs and Diagnostic Strategies 25.06.2026 3min

  Guest: Valmiki Maharaj, MD With increasing recognition and more accessible diagnostic tools, ATTR-CM can no longer be overlooked in patients with atypical heart failure presentations. Dr. Valmiki Maharaj shades insights on connecting clinical clues, confirming diagnosis efficiently, and acting earlier to meaningfully impact long-term outcomes. He's the Director of the Heart Failure Clinic, the Cardiac Amyloidosis Clinic, and the Cardiovascular Disease Fellowship Program at the University of Minnesota Medical School.
• 
  Diagnosing ATTR-CM: Recent Advances and Future Directions 25.06.2026 2min

  Guest: Ronald Witteles, MD Even with growing awareness of transthyretin amyloid cardiomyopathy (ATTR-CM), delays in diagnosis remain a significant challenge. That's why Dr. Ronald Witteles, Professor of Cardiovascular Medicine at Stanford Medicine and Co-Director of the Stanford Amyloid Center, joins us to share practical strategies for recognizing ATTR-CM, implementing the appropriate diagnostic pathway, and overcoming common testing pitfalls.
• 
  When to Suspect ATTR-CM: Clues for Earlier Diagnosis 25.06.2026 4min

  Guest: Ronald Witteles, MD What clinical clues should raise suspicion for transthyretin amyloid cardiomyopathy (ATTR-CM)? Find out as Dr. Ronald Witteles examines the cardiac and extracardiac manifestations that can help us recognize this often-overlooked disease. He's a Professor of Cardiovascular Medicine at Stanford Medicine and the Co-Director of the Stanford Amyloid Center and Multidisciplinary Sarcoidosis Program.
• 
  Understanding the Mechanisms Behind Resistant Hypertension 17.06.2026 12min

  Host: Steve Jackson, PharmD Guest: Jan Basile, MD Guest: Michael J. Bloch, MD, FAHA, FASH, FNLA When blood pressure remains uncontrolled despite treatment, adding more medications may not address the underlying cause. In this expert-led discussion, Drs. Jan Basile and Michael Bloch join Dr. Steve Jackson to examine often-overlooked drivers of hypertension, including aldosterone excess, volume overload, medication adherence, and blood pressure measurement challenges. Learn how a deeper understanding of these drivers can help us distinguish resistant hypertension from pseudo-resistance and individualize treatment decisions for our patients. Dr. Basile is a Professor in the Division of Cardiology at the Medical University of South Carolina in Charleston. Dr. Bloch is a Clinical Assistant Professor in the Department of Internal Medicine at the University of Nevada School of Medicine and the Medical Director of Vascular Medicine and Anticoagulation Services at the Renown Institute for Heart and Vascular Health in Reno. This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.
• 
  Quality of Life Conversations in ATTR-CM Care 27.05.2026 2min

  Guest: Kevin S. Shah, MD Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience significant quality of life challenges that extend beyond cardiac symptoms, including reduced mobility, fatigue, mood changes, and loss of independence. Dr. Kevin Shah discusses practical, patient-centered strategies to identify functional limitations, support emotional well-being, engage caregivers, and align treatment goals with what matters most to these patients. Dr. Shah is an Advanced Heart Failure and Transplant Cardiologist at Long Beach Memorial Hospital, as well as an Associate Professor of Medicine at the University of California Irvine School of Medicine.
• 
  Hypertension Across Diverse Populations: Practical Strategies for Equitable Care 15.05.2026 12min

  Host: Alexandria May, PharmD, BCPS Guest: Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA Hypertension is a key modifiable cardiovascular risk factor, but its prevalence, progression, and outcomes vary significantly across patient populations. In this program, Dr. Alexandria May and Dr. Keith Ferdinand discuss how social drivers of health, geography, access to care, and comorbid conditions can influence risk and outcomes. Tune in to find out how we can better address variation in hypertension across patient groups. Dr. Ferdinand is the Gerald S. Berenson Chair in Preventive Cardiology and the Director of Preventive Cardiology at Tulane University School of Medicine in New Orleans. This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.